Journal Mobile Options
Table of Contents
Vol. 5, No. 1, 1995
Issue release date: 1995
Section title: Original Paper
Cerebrovasc Dis 1995;5:21–25
(DOI:10.1159/000107813)

Atenolol in Secondary Prevention after Stroke

Eriksson S. · Olofsson B. · Wester P.
Department of Internal Medicine, University Hospital of Northern Sweden, Umeå, Sweden

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Published online: 2/22/1995
Issue release date: 1995

Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 0

ISSN: 1015-9770 (Print)
eISSN: 1421-9786 (Online)

For additional information: http://www.karger.com/CED

Abstract

This study investigated the effect of 50 mg atenolol in reducing the risk of death, stroke and myocardial infarction after stroke and transient ischaemic attacks (TIA). The study was designed as a Swedish multicentre, randomised, double-blind, parallel group study with randomisation stratified according to age and prognostic score. Seven hundred and twenty patients aged over 40 years who had no contraindications to beta-blockers were included within 3 weeks of a stroke or TIA, with 372 patients (mean age 70.7 years) randomised to the treatment and 348 patients (mean age 70.1 years) to the placebo group. Major strokes made up the index events in 81% of patients in the treatment and 79% of those in the placebo group. The two groups were similar in respect to baseline characteristics. The index event was classified as an ischaemic stroke in 86.8 and 86.3% of patients in the treatment and placebo groups, respectively. Side effects of atenolol and placebo caused 17 and 10% of patients to withdraw from allocated treatment. During the follow-up period (mean 28 months) 51 patients in the treatment group died compared to 60 in the placebo group [relative risk with 95% confidence interval 0.79 (0.54–1.16)] and 74 patients in the treatment group suffered a further major stroke compared to 69 in the placebo group. Twenty-six and 29 patients, respectively, suffered an acute myocardial infarction. Calculations using survival techniques and Cox''s proportional hazard model indicated a reduced risk of death (21%) and myocardial infarction (7%) in the treatment group with no reduction in the risk of further stroke. None of these reductions was statistically significant. Thus the study failed to confirm a statistically significant reduction in death, stroke or myocardial infarction after major stroke or TIA by 50 mg atenolol. However, the results do not exclude a possible secondary prophylactic effect of atenolol in secondary prophylaxis after stroke and TIA.

© 1995 S. Karger AG, Basel


  

Author Contacts

Dr. B.-O. Olofsson, Department of Internal Medicine, University Hospital of Northern Sweden, S–901 85 Umeå (Sweden)

  

Article Information

Received: November 11, 1993
Accepted: September 2, 1994
Number of Print Pages : 5

  

Publication Details

Cerebrovascular Diseases

Vol. 5, No. 1, Year 1995 (Cover Date: 1995)

Journal Editor: Hennerici, M.G. (Mannheim)
ISSN: 1015–9770 (print), 1421–9786 (Online)

For additional information: http://www.karger.com/CED


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Published online: 2/22/1995
Issue release date: 1995

Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 0

ISSN: 1015-9770 (Print)
eISSN: 1421-9786 (Online)

For additional information: http://www.karger.com/CED


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.